New Drug Approvals
August 19th, 2009
Although, prGCD, a new drug used to treat patients with a unique genetic disorder - Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.
August 17th, 2009
Novartis has recently announced the U.S. FDA approval of their multiple sclerosis treatment drug: Extavia (Interferon beta 1-b). The FDA approved the drug for patients that suffer from a relapse of the auto immune disease, or for those patients whom are newly diagnosed with MS.
August 17th, 2009
The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.
August 7th, 2009
Baxter International has recently announced that they have finished the production of their first commerical batches of CELVAPAN A/H1N1 pandemic vaccine. Currently, Baxter is discussing distribution options with national health authorities, so long as they receive appropriate permission. Baxter implemented their proprietary Vero cell production technology when developing CELVAPAN.
August 7th, 2009
Recently, the US FDA has approved a once-daily tablet to treat adult Type 2 Diabetes. Along with diet and exercise, Onglyza will assist to manage high blood sugar levels.
August 7th, 2009
The US FDA has recently approved Invega Sustenna extended-release injectable suspension for acute and maintenance therapy of adult schizophrenia. Invega Sustenna is the first US approved once a month injectable, long-acting, atypical antipsychotic.
August 6th, 2009
The US FDA has reported seasonal influenza vaccine approval for 2009 and 2010.
August 6th, 2009
The US FDA has officially announced their approval to market Onsolis, an advanced treatment used for the management of breakthrough pain, for cancer patients over the age of eighteen, who already receive and have built a tolerance to opiod therapy for unrelenting cancer pain
August 6th, 2009
Women who experience contraceptive failure or who have engaged in unprotected sex, may be relieved to know that Teva Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has recently approved a New Drug Application for Plan B, One- Step Emergency Contraceptive.
